The positive results from the ASCO presentation of Affimed's AFM24 in combination with NKGen Biotech's SNK01 NK Cells could potentially boost investor confidence in Affimed. Stable disease was observed in three out of seven heavily pretreated patients, and no dose-limiting toxicities or unexpected toxicities were observed. This indicates that the treatment is not only effective but also safe, which could make it more attractive to investors.